Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Co., Ltd. has submitted its IPO application to the Hong Kong Stock Exchange after a lengthy history of attempts, with significant changes in ownership and financial performance over the years [1][2]. Company Overview - Xinhehua was established in 2001 and has faced multiple challenges in its IPO journey, including a failed attempt in 2012 due to financial fraud allegations and another withdrawal in 2021 [1]. - The company's actual controller, Jiang Yun, has increased his shareholding from 29.81% to 65.2% over the years, indicating a stronger commitment to the company [1]. Financial Performance - Xinhehua ranked second in China's traditional Chinese medicine market by revenue in 2023, with a compound annual growth rate (CAGR) of 27% from 2022 to 2024 [2]. - The company reported revenues of 1.145 billion RMB in 2023, with a profit of 104 million RMB, but projected a decline in profit to 89.11 million RMB in 2024 despite revenue growth to 1.249 billion RMB [2][3]. Product and Profitability - Xinhehua's product offerings include ordinary and toxic traditional Chinese medicine slices, with both categories experiencing declining gross margins [4]. - The gross margin for toxic slices decreased from 29.7% in 2022 to 19.1% in 2024, while ordinary slices fell from 19.6% to 16.7% in the same period [4]. Customer Base and Market Strategy - The revenue from the top five customers has increased, but customer retention rates have declined significantly from 86.5% in 2022 to 63.6% in 2024 [5]. - Xinhehua plans to expand its product offerings and market presence, including launching a personalized herbal health supplement platform by April 2025 and developing online sales channels [5].
屡败屡战！新荷花创业板两度铩羽后转道港交所，中药饮片龙头能否圆上市梦